Tarsus Pharmaceuticals stock price target raised to $106 by H.C. Wainwright
H.C. Wainwright raised its price target on Tarsus Pharmaceuticals (NASDAQ:TARS) to $106 from $88, citing strong sales of XDEMVY, its FDA-approved treatment for Demodex blepharitis. The company reported $194.6M in Q3 sales, up 64% YoY, but a wider-than-expected loss of $14.4 per share. Tarsus maintains a strong cash position and raised its sales outlook.
How this was made
The 30-second read
Why it matters
Analyst target raise reflects confidence in product XDEMVY despite profitability concerns.
Market read
The upgrade may prompt short‑term buying interest in TARS, while peers may see modest spillover.
What to watch
The company posted a large adjusted loss of $14.4 per share, which could temper enthusiasm.
Background
Tarsus Pharmaceuticals recently reported Q3 revenue of $194.5 million, beating forecasts, but posted a wide adjusted loss.
Ticker impact
H.C. Wainwright raised its price target on Tarsus Pharmaceuticals to $106 from $88, maintaining a Buy rating.
likely upward pressure as investors price in the higher target.
Target increase of $18 represents a 20% upside from current price, indicating fresh bullish sentiment.
Market effects
Positive outlook for ophthalmology biotech may lift peer stocks in the eye‑care therapeutic space.
Limited to U.S. biotech sector; no broader regional effect.
Minimal global impact beyond niche biotech investors.
Counterpoint
Target raise may already be priced in; upside could be limited if earnings miss persists.
Key entities
- companyTarsus Pharmaceuticals
NASDAQ‑listed biotech focused on Demodex blepharitis treatment.
- analyst_firmH.C. Wainwright
Equity research firm that issued the price target upgrade.
